May 2020 - Channelchek

Robust Q1 Results With 34 Percent Sales Growth

Posted on May 29, 2020 by Admin

Friday, May 29, 2020

Ceapro (CRPOF)(CZO)

Robust Q1 Results With 34% Sales Growth

Ceapro, Inc. is a publicly-held (TSX-V: CZO, OTCQX: CRPOF) Canadian biotechnology company developing and commercializing “active ingredients” for the healthcare and cosmetic industries. Ceapro’s active ingredients are primarily derived from oats and other renewable plant resources. The Company utilizes its proprietary plant extraction-based manufacturing process to supply active ingredients based on “oat beta glucan and avenanthramides”. Ceapro has patented a technology known as “Pressurized Gas eXpanded (PGX) technology”, which has superior features when compared to conventional drying and purification technologies. Using PGX technology, Ceapro generates novel biopolymers and biocomposites with micro/nanoparticles.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Solid Q1/F2020. Ceapro yesterday announced financial results for the first quarter of F2020. Despite the ongoing COVID-19 pandemic, the quarter was highlighted by strong results as Ceapro reported a net profit of $1.126 mm compared to a net loss of $(0.64) mm in Q1/F2019. Product sales in the quarter increased 34% relative to Q1/F2019.

Revenue growth driven by avenanthramides sales. The 34% growth in total revenue relative to last year’s quarter was primarily attributed to a 68% increase in avenanthramides sales. In Q1/F2020, Ceapro generated CFO of $0.531 mm versus CFO of $0.367 mm in Q1/F2019. In the quarter, gross margin increased to…

Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.

Lead Drug Gets Fast Track Designation by FDA

Posted on May 29, 2020 by Admin

Friday, May 29, 2020

Cardiff Oncology (CRDF)

Lead Drug Gets Fast Track Designation by FDA

Cardiff Oncology (formerly Trovagene, Inc.) is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment. We have three ongoing clinical programs that are demonstrating the safety and efficacy of onvansertib: a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin® in KRAS-mutated metastatic colorectal cancer (mCRC); a Phase 2 study of onvansertib in combination with Zytiga® (abiraterone)/prednisone in Zytiga-resistant metastatic castration-resistant prostate cancer (mCRPC); and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML). For more information, please visit https://www.cardiffoncology.com.

Cosme Ordonez, MD, Ph.D., Senior Life Sciences Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Cardiff Oncology Fast Track Designation. Cardiff yesterday announced that the U.S. FDA granted Fast Track Designation to onvansertib, which will likely expedite development and FDA review of the drug. The Fast Track Designation was given to onvansertib for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC).

Lead drug effective in 88% of mCRC patients. Interim results recently presented at ASCO 2020 from a Phase Ib/II clinical trial on the use of onvansertib for the treatment of metastatic colorectal cancer (mCRC) patients carrying KRAS mutations showed that seven out of eight patients (88%) responded to…

Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Coeur Mining (CDE) – Increasing 2021 Estimates

Posted on May 29, 2020 by Admin

Friday, May 29, 2020

Coeur Mining (CDE)

Increasing 2021 Estimates

Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, rochester, wharf, and kensington. Its projects are located in the United States, Canada and Mexico, and North America.

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Coeur augments leadership team. Coeur hired Mr. Michael Routledge as Senior Vice President and Chief Operating Officer effective June 1, 2020. He will assume responsibility of Coeur’s operations from Mr. Terry Smith who will serve as Senior Vice President and Chief Development Officer. In our view, Mr. Routledge’s appointment augments the leadership team to support long-term growth initiatives, including the planned expansion of Rochester, preliminary feasibility study at Silvertip and exploration activities.

Updating estimates. We are narrowing our 2020 loss per share estimate to $(0.02) from $(0.03) and increasing our 2021 EPS estimate to $0.15 from $0.12. Our 2020 and 2021 EBITDA estimates are $182.2 million and $236.8 million, respectively. The revisions are due primarily to higher commodity price and revenue assumptions. During the second quarter, gold and silver futures prices increased 7.6% and…

Click to get the full report.

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Increasing 2021 Estimates

Posted on May 29, 2020 by Admin

Friday, May 29, 2020

Coeur Mining (CDE)

Increasing 2021 Estimates

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Click to get the full report.

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Which Major Index Outperforms in June?

Posted on May 29, 2020 by Admin

Is the Repeated Outperformance in June of the Russell 2000 Random?

“Sell in May and Go Away” is an investment axiom that suggests investors would do better to lighten their positions in stocks during the summer months. Is this good advice? It doesn’t tell us when in May that we should take our chips off the table. Is it May 1, Memorial Day weekend, May 31? And, is one sector or index more impacted than others? This May, the Nasdaq hit its low for the month on May 3, right before its 800 point climb. The S&P 500 bottomed later on May 14 before shooting up close to 10%. Overall, May 2020 was an excellent month for the major market indexes. If you didn’t sell, there’s a good chance it gave a boost to your portfolio.

What will June and the summer bring? I don’t know of any market sayings for June. I guess you were supposed to have already reduced your positions in May. I do know, from my years on Wall Street, that the trading desks during the summer months are often controlled by the rookies and interns. They’re often trying to demonstrate their abilities while the veterans are out playing golf or lying on a beach in South Hampton. Could this be the root of the “sell in may…” advice?

Serious investors don’t care about sayings; they care about company data, economic numbers, trends, and probabilities. I decided to look back at the trends over the past 20 Junes to see if history provided a verifiable pattern across the most followed market benchmarks.

June
Results Since 2000

Out of the past 20 years, the Russell 2000 has returned positive results 13 times (65%). This doesn’t sound overly impressive until you compare it to the Dow 30 which had been up in June for only 7 of the years (35%), the S&P 500 was up 11 of the 20 (55%), or the Nasdaq that was up 9 Junes (45%) over the past 20 years. So, over the period, only two indexes were up during June more than half the time. I should point out here that this 20-year period was not “cherry-picked” to compare performance history. A quick review of the data for the ten years prior to this, and the ten years prior to that only reinforced this June “trend” with the small-cap index exceeding the others. Here is a link for the Underlying Data.

Data Source: investing.com

In terms of performance, the track record for the Russell 2000 is even more compelling. With a one-month return average of almost 1% (0.94%) in June since 2000, the Russell has returned more than double the next closest index which is Nasdaq.

There May Be a Reason

Rather than caution that past history is not an indication of future performance, I’ll instead make sure readers know that during this period, the best year was 6.89% (June 2019), and the worst June was negative 8.60% (June 2008). So any particular year has its own circumstances. But there is something at play during June with this index. The Russell Indexes are being reworked and this creates activity that could be providing a predictable tailwind. The added companies typically have a good amount of new interest surrounding them. This added interest causes fresh institutional buyers of the new stocks being included and often a rise in their value leading up to and for a short time after their inclusion.

Take Away

Channelchek wrote two informative articles on the impact on investors of index reconstitution. They are Opportunity When Stock Market Indices
are Reshuffled and The Russell Index Reconstitution. These two articles, coupled with the above data, make clear that investors should be aware of how the calendar impacts the index, which measures the lower 2000 stocks of the 3000 largest capitalized companies.

As far as selling everything else now that it’s the last day in May, normal market probabilities may not apply this year. The one thing certain in 2020 is that there are cross-currents that will continue to move markets dramatically. The normal drivers of stock price based largely on recent company performance, for now, are on hiatus.

Paul Hoffman

Managing Editor

Ceapro (CRPOF)(CZO) – Robust Q1 Results With 34 Percent Sales Growth

Posted on May 29, 2020 by Admin

Friday, May 29, 2020

Ceapro (CRPOF)(CZO)

Robust Q1 Results With 34% Sales Growth

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Cardiff Oncology (CRDF) – Lead Drug Gets Fast Track Designation by FDA

Posted on May 29, 2020 by Admin

Friday, May 29, 2020

Cardiff Oncology (CRDF)

Lead Drug Gets Fast Track Designation by FDA

Cosme Ordonez, MD, Ph.D., Senior Life Sciences Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Euroseas Ltd. (ESEA) – Strong Quarter, But Challenges Ahead

Posted on May 28, 2020 by Admin

Thursday, May 28, 2020

Euroseas Ltd. (ESEA)

Strong Quarter, But Challenges Ahead

Euroseas Ltd. provides ocean-going transportation services worldwide. The company owns and operates containerships that transport dry and refrigerated containerized cargoes, including manufactured products and perishables; and drybulk carriers that transport iron ore, coal, grains, bauxite, phosphate, and fertilizers. As of March 31, 2017, it had a fleet of seven containerships; and six drybulk carriers, including three Panamax drybulk carriers, one Handymax drybulk carrier, one Kamsarmax drybulk carrier, and one Ultramax drybulk carrier. The company was founded in 2005 and is based in Maroussi, Greece.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Adjusted 1Q2020 EBITDA, excluding dry dock expenses, of $4.1 million was above expectations by $1.2 million. The positive impact from two recent acquisitions, higher TCE rates and lower opex more than offset higher-than-expected downtime. 1Q2020 gross TCE revenue of $15.5 million increased from $13.2 million in 4Q2019 due to a $529 increase in TCE rates to $9,615/day from $9,086/day, which more than offset 21 higher off hire days.

Adjusting 2020 EBITDA estimate. Weaker container market fundamentals and scrapping activity more than offset positive 1Q2020 variance. The recent acquisitions will have a full impact on 2020 operating results and we are forecasting 2020 EBITDA of $12.1 million based on 6,070 operating days, down from our previous estimate of $15.3 million and TCE rates of $9,373/day from a previous estimate of $9,691/day. Operating days are expected to drop to 6,070 with…

Click to get the full report.

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Strong Quarter, But Challenges Ahead

Posted on May 28, 2020 by Admin

Thursday, May 28, 2020

Euroseas Ltd. (ESEA)

Strong Quarter, But Challenges Ahead

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Click to get the full report.

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Trading Technology Continues to Level the Playing Field for Investors

Posted on May 28, 2020 by Admin

Has Robinhood, the Online Brokerage Disruptor, Been Disrupted?

Stockbrokers with zero commissions may have recently become too expensive. We know that online brokers and trading apps like Robinhood, IBKR Lite, Webull, Etrade, and most discount brokers, have over time, discounted their way to zero-commission trades. The market is still getting accustomed to this money-saving win for highly active traders. The change also eliminated the commission hurdle that thinly traded companies and their would-be investors once had accumulating shares. Multiple transactions now cost the same as one, and that price is $0.00. In 2020 odd-lot transactions are an almost ancient concept as zero commissions don’t dictate blocks of 100 share round lots. No cost in and no cost out with no share or dollar minimum has opened the market to many more investors.

How Do Zero
Commission Platforms Make Money?

A significant source of income to zero- commission brokers that is invisible to the account holder is the idle cash in their accounts. This uninvested cash, per customer agreement, is “swept” into a banking arm or affiliate of the broker. The customer is compensated for the cash balances, currently below 0.5%, but the broker earns far more. The cumulative idle cash can be substantial. According to Bloomberg, during Summer 2019, Schwab held customer cash totaling $265 billion; this earned them more than $5.7 billion in revenues. TD Ameritrade’s revenue was bolstered by $1.2 billion, and E*Trade, $1.8 billion. It isn’t difficult for the broker to earn a spread to 0.5% or less and impact company earnings. The use of customer cash as their own resource to generate revenue makes it still very much worthwhile to charge customers zero. This is especially true as using no commissions to attract new business grows a broker’s account base and perhaps bottom-line.

Stockbrokers also make fees when lending money to customers with margin accounts. The more active accounts there are, the more potential there is for profit. Another business they may be involved in is securities lending. This is a profitable business that most brokerage customers don’t know about. It occurs as a result of short-sale transactions (short-selling), by providing “good” delivery to the buyer(s). These transactions are completed by lending securities from customer accounts at a rebate (interest) rate. A securities lending operation at a brokerage can turn a good profit from their accounts on fully collateralized loans.

Another meaningful addition to earnings is “payment for order flow.” This is when the broker earns fees from another firm for forwarding their clients buys and sells to computerized trading firms. These firms match buyers with sellers and earn the bid/offer spread.

What’s
Better than Free?

There is now a brokerage platform that has a more generous business model. They keep track of what an account has been worth to them and then discount a portion back to the customer. This is, in effect, “cheaper than free.” It’s unclear if this reinvented service will compel people to leave their broker for this new entrant, but for those counting every penny, this is something to be aware of. The broker has the kind of name that doesn’t roll off the tongue easily. It’s called “All of Us Financial.” The website is also almost decidedly, not in the mold of Wall Street brokers. Below is what their website wants you to know about All of Us Financial before they tell you anything else:

Competition
is Good for Consumers

In a recent update to their blog by CEO Alan Grujic, All of Us appears to be wedging itself against both the large Wall Street firms and newer innovative, disruptive firms like Robinhood. The big differentiators they offer are transparency and customers earning on more than just their stock trading success. This, of course, is because of the revenue sharing component of the service. In a company blog, Mr. Grujic wrote, “There is nothing wrong with Robinhood’s revenue model – in fact, it’s how many brokerages make money. But just because something isn’t wrong doesn’t mean there isn’t a better way. And just because a company disrupts the status quo doesn’t mean it shouldn’t be disrupted even more.” He finishes by saying, “For those who have grown disillusioned with Robinhood’s sleight of hand, join the movement at All of Us and help rewrite the rules by putting your rights as investors before the wants of Wall Street.”

This will be an interesting experiment as this new entrant tries to disrupt the disruptors. It will also help show how loyal investors are to their brokers in 2020. In the past, it was difficult for a new company to win business away from established brokerage businesses. That loyalty has been fading.

Take Away

In CEO Alan Grujic’s words, “My current focus is on building an investor empowerment platform, which I believe will revolutionize the way investing is done. I am convinced this is ‘the inevitable’ path down which the convergence of finance and technology will lead.” In recent years technology has provided information at no cost to self-directed investors at a level once reserved for large institutional investors. As a no-cost platform that provides top-tier research and analysis to registered users, Channelchek is also part of the empowerment movement that is leveling the playing field for all investors.

The brokerage community has proven what once seemed mathematically impossible. A
business can offer something for free and make it up in volume. This is beneficial for corporate finance and particularly helpful to smaller, more thinly traded companies and investors that now find it easier to own shares.

Suggested Reading:

Investment
Barriers Once Seen as Insurmountable are Falling Fast

Investment
Portfolios are Checked Twice as Often by Millennials

Contango,
ETFs, and Alligators

Enjoy Premium Channelchek Content at No Cost

Sources:

Brokers
Profit From You Even If They Don’t Charge for Trading

In the Race to Zero-Fee Broker Commissions, here’s who
the Big Winner is

All of
Us Financial

Ceapro Inc. Reports 2020 First Quarter Financial Results and Highlights

Posted on May 28, 2020 by Admin

Ceapro Inc. Reports 2020 First Quarter Financial Results and Highlights

(Note: companies that
could be impacted by the content of this article are listed at the base of the
story [desktop version]. This article uses third-party references to provide a
bullish, bearish, and balanced point of view; sources are listed after the
Balanced section.)

– Maintained production operations during COVID-19 pandemic crisis, providing our customers essential products while ensuring the health and safety of our employees –

– R&D activities focused on the development of innovative delivery systems –

– First quarter 2020 sales increased 34% vs. first quarter 2019 –

– Net profit of $1,126,000 for Q1 2020 vs. net loss of $637,000 for Q1 2019 –

EDMONTON, ALBERTA – May 28, 2019 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the first quarter ended March 31, 2020.

“We are very pleased with the progress we have made on multiple fronts during the first quarter of this year, despite the COVID-19 pandemic crisis. While our first quarter financial results were very strong, our focus remains on the health and safety of our associates during these unprecedented times, followed by business continuity. These solid results are a clear testament to the dedication and hard work of every one of our employees during these challenging times and we are very proud of their commitment to support our customers heightened demand by delivering high quality products. Importantly, these results also reflect the sound foundation and the strength of our base business deliberately built over the last few years,” stated Gilles Gagnon, M.Sc., MBA, President and CEO.

Corporate and Operational Highlights

Pipeline Development:

• Received approval from Health Canada for an amendment to the beta glucan clinical trial protocol to allow evaluation of subjects with confirmed pathophysiological condition of hyperlipidemia who voluntary request to be treated with beta glucan only, without regular dosing of statins. This, allowing patients to receive beta glucan as a stand-alone therapy, should accelerate patient enrollment and expand target addressable patient population.

• Received approval from Health Canada Controlled Substances and Cannabis Branch for a research license with medical cannabis for the formulation of unique solid cannabinoid delivery systems using PGX technology.

• Published Results from a collaborative project with University of Alberta researchers in Journal of Supercritical Fluids in an article titled “Preparation of PGX-dried gum arabic and its loading with coQ10 by adsorptive precipitation.”

• Continued to monitor stability studies for liquid beta glucan and avenanthramides produced at a new manufacturing site as well as for the pharmaceutical-grade dry powder formulation of avenanthramides to be used in a human bioavailability study.

• Developed new PGX-dried chemical complexes like sodium alginate and gum arabic impregnated with coenzyme Q10 demonstrating the versatility of the PGX technology and the potential to develop significant bioactives delivery systems.

Technology:

• Advanced conversations with interested potential partners to out-license applications developed using Ceapro’s innovative technology.

• Conducted a technical assessment of available equipment in Europe and North America and are actively evaluating locations for a future commercial scale-up of the PGX technology.

• Advanced research and development efforts to pursue the development of new PGX-dried chemical complexes for potential applications under various forms like pills, capsules, fast dissolving strips and face masks.

• Executed on research collaboration projects with Universities of Alberta and McMaster for the impregnation of various bio actives using PGX-processed dry beta glucan as a potential delivery system for multiple applications in healthcare.

• Subsequent to quarter, announced research project with McMaster University for PGX-processed yeast beta glucan as a potential treatment for COVID-19 patients.

Corporate:

• Hired an international consulting firm to support licensing activities.

• Secured DTC Eligibility for publicly traded shares under Ticker OTCQZ: CRPOF.

• Increased Company exposure through investor relations activities.

Financial Highlights for the First Quarter Ended March 31, 2020

• Total sales of $4,273,000 for the first quarter of 2020 compared to $3,197,000 for the comparative period in 2019; an increase of 34% over last year. Avenanthramides sales volumes increased by 68% for Q1 2020 vs Q1 2019.

• Net income after taxes of $1,126,000 for the first quarter of 2020 compared to a net loss after taxes of $637,000 for the comparative period in 2019.

• Research and Development of $503,000 in Q1 2020 vs $801,000 in 2019. This decreased investment was partly due to a slowdown of recruitment of patients for the beta glucan trial during the pandemic crisis.

• Cash generated from operations of $531,000 in Q1 2020 vs. cash flows generated from operations of $367,000 in Q1 2019.

• Positive working capital balance of $6,263,817 as of March 31, 2020.

“As we respond to the potential impacts and uncertainties of COVID-19 by taking the necessary steps to preserve our financial position, we continue to execute on our transition to a new business model from a contract manufacturer to a biopharmaceutical company. We remain dedicated to executing on our milestones ahead and depending on the pandemic situation, look forward to what we believe will be an exciting year,” concluded Mr. Gagnon.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

For more information contact:

Jenene Thomas

JTC Team, LLC

Investor Relations and Corporate Communications Advisor

T (US): +1 (833) 475-8247

E: czo@jtcir.com

Issuer:

Gilles R. Gagnon, M.Sc., MBA President & CEO T: 780-421-4555

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Newrange Gold (NRGOF)(NRG:CA) – Drilling Commences at the Pamlico Project in Nevada

Posted on May 28, 2020 by Admin

Thursday, May 28, 2020

Newrange Gold (NRGOF)(NRG:CA)

Drilling Commences at the Pamlico Project in Nevada

As of April 24, 2020, Noble Capital Markets research on Newrange Gold is published under ticker symbols (NRGOF and NRG:CA). The price target is in USD and based on ticker symbol NRGOF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.
Newrange Gold Corp is an exploration stage company focused on acquiring and exploring exploration and evaluation assets in Colombia and the United States. The Company operates in a single reportable operating segment-the acquisition, exploration, and development of mineral properties. Some of the projects acquired by the company are Pamlico gold project in Nevada and Rocky mountain project in Colorado. The company also holds an interest in the Yarumalito property, El Dovio property and Anori property in Colombia.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Drilling program begins at Pamlico. Newrange Gold has commenced drilling at its Pamlico project in Nevada. The initial portion of the program involves drilling 30 to 35 holes for a total of 3,000 to 3,500 meters, primarily along Pamlico Ridge. Reverse circulation (RC) drilling will be used to test the continuity of near-surface gold around and between historic workings of the Pamlico, Gold Bar and Good Hope mines. Once additional sites are permitted and roadwork is completed, drilling will continue with a combination of RC and diamond drilling at identified targets. The program is expected to result in up to 10,000 meters of drilling over the next several months.

Agreement for sale of remaining non-core Colombian assets. As expected, Newrange Gold announced a definitive agreement for the sale of the company’s remaining non-core Colombian assets to Andean Mining Corporation, a private Australian company. As part of the agreement, Newrange Gold will receive…

Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Drilling Commences at the Pamlico Project in Nevada

Posted on May 28, 2020 by Admin

Thursday, May 28, 2020

Newrange Gold (NRGOF)(NRG:CA)

Drilling Commences at the Pamlico Project in Nevada

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Click to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).